Cerner’s president leaves for Trizetto

  • 15 July 2010

The president of Cerner Corporation is to leave the company and take up a new position as the chief executive of Trizetto Solutions.

Trace Devanney had been due to relocate to London this summer to head up Cerner’s international operations and expansion.

Devanny’s responsibilities will be taken on by the current top management. Long term Cerner chairman and chief executive Neal Patterson will now also take on the title of president.

Trace is a highly experienced and growth-focused leader,” said TriZetto founder and chairman Jeff Margolis. Trizetto focuses on integrated care management with a strong position in the US, plus international clients.

“Having been part of a leadership team that enjoyed tremendous growth at Cerner, I look forward to helping TriZetto capitalize on the many new growth opportunities it has created,” Devanny said ina statement.

Devanny joined Cerner in 1994 and has been the president of Cerner since 1999, a period during which Kansas City based health It company has enjoyed remarkable growth.

During his tenure the company Devanny led the company’s five-fold expansion in revenue, including creating the company’s global presence and brand.

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

Taking the robot out of the human to make more time for patient care

Taking the robot out of the human to make more time for patient care

A robotic process automation (RPA) programme implemented in June 2024 by Calderdale and Huddersfield NHS Foundation Trust (CHFT) at its two hospitals in West Yorkshire…
Digital Health Coffee Time Briefing ☕

Digital Health Coffee Time Briefing ☕

Today's news roundup covers Dictate.IT's new AI clinical assistant and an ORCHA-approved gardening app to support mental wellbeing.
Kidney Beam secures seed funding for exercise and lifestyle app

Kidney Beam secures seed funding for exercise and lifestyle app

An evidence-based kidney care app has secured £610,000 in seed funding, including a sizeable contribution from charity Kidney Research UK.